Autoimmunity & calming an over-active response
One of 5 mechanistic pathways to 🛡️ Immune resilience · 16 options
The opposite problem, and one that 'immune boosting' actively worsens. Here the goal is restoring regulatory T-cell function and resolving inflammation properly — modulation rather than stimulation, and the distinction is not academic.
Antibodies appear years before symptoms do. Thyroid antibodies in particular are worth knowing with a normal TSH, because they change how you'd approach iodine and selenium entirely.
ANA (Antinuclear Antibodies)Rheumatoid FactorThyroid Antibodies (TPO + TgAb)hs-CRP (High-Sensitivity C-Reactive Protein)ESR (Sed Rate)Vitamin D (25-Hydroxy)🛡️ Autoimmune Screen covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
💉 Low Dose Naltrexone
TLR4 antagonism plus endorphin rebound. Small trials in Crohn's, fibromyalgia and multiple sclerosis are encouraging; it is cheap, low-risk and badly under-studied.
💉 VIP
Shifts macrophages toward the M2 regulatory phenotype and induces regulatory T-cells.
💉 KPV
Anti-inflammatory at mucosal surfaces, with interest in inflammatory bowel disease.
💉 Thymosin Alpha 1
Modulates rather than stimulates, which is why it does not carry the autoimmune concern that true immune stimulants do.
🧬 Vitamin D
Promotes regulatory T-cell development. Deficiency is associated with multiple autoimmune conditions, and latitude gradients in MS incidence are among the strongest environmental signals in the field.
🧬 Omega-3 (Fish Oil)
Resolvin substrate; trial evidence for reduced disease activity in rheumatoid arthritis.
🧬 SPMs (Pro-Resolving Mediators)
The resolution signal itself — the mechanism that is supposed to end inflammation and fails to in chronic disease.
🧬 Curcumin
NF-κB inhibition with trial evidence in rheumatoid arthritis and ulcerative colitis.
🧬 Boswellia
5-LOX inhibition with trial data in inflammatory bowel disease and osteoarthritis.
🧬 Palmitoylethanolamide (PEA)
Mast-cell and glial modulation with a very clean safety profile.
🧬 UC-II Collagen
Oral tolerance induction — deliberately teaching the immune system to stop attacking a self-antigen. One of the most interesting mechanisms in supplement form.
🧬 Probiotic
Regulatory T-cell induction via the gut; the microbiome shapes systemic immune tolerance.
🧬 Selenium
Reduces thyroid peroxidase antibodies in Hashimoto's in several trials — a specific, measurable autoimmune endpoint.
🧬 NAC
Glutathione restoration in tissues under oxidative stress.
🧬 Luteolin
Mast-cell stabilization, relevant in mast-cell activation presentations.
💉 Epobis
The EAE result is the single most specific in vivo finding for this peptide: systemic Epobis delayed the onset of clinical signs in a rat model of multiple sclerosis, with the mechanistic correlate being reduced TNF release from activated macrophages and microglia. Note the exact verb — DELAYED the clinical signs, not prevented or reversed them — and note that a delay in an induced rodent autoimmune model is the weakest form of a real result rather than a strong one. Nobody has dosed it in any autoimmune condition in a person.
What actually decides this outcome, in order of size
This is the half of the immune goal where more response is the problem, and almost everything sold under the word immunity points the other way. Ranked by how much of the outcome each one owns:
- Whether there is a diagnosis and a treating clinician, because autoimmune disease is managed rather than supplemented. Every item below is an adjunct to that, and several of them interact with immunomodulatory prescriptions. Nothing on this page is a diagnosis, and stopping a disease-modifying drug to try any of it is the single worst decision available here.
- Whether prevention or modulation is the question, because one of them now has randomized evidence. Vitamin D and marine omega-3 supplementation reduced incident autoimmune disease in a large randomized trial Hahn 2022, and outcomes two years after the intervention stopped were reported separately Costenbader 2024. That is an unusually strong result for a supplement and it is about incidence rather than about treating established disease.
- Which antibody you are being shown, because a titer is not a symptom. Selenium supplementation decreased thyroid peroxidase antibodies in autoimmune thyroiditis Gartner 2002. That is a real, replicated, measurable effect on an antibody, and whether it changes thyroid function or the need for replacement is a separate question the antibody result does not answer.
- Whether inflammation is being suppressed or resolved, because they are different programs. Resolution is an active process driven by specialized pro-resolving mediators, reviewed in a precision-nutrition frame Al-Shaer 2021, and it is the mechanism that fails in chronic disease. Suppression is what most anti-inflammatories do. Inflammation resolution (not suppression) argues that distinction at length.
- Whether the mechanism is tolerance induction, which is the most interesting thing on this page. Undenatured type II collagen works by oral tolerance rather than by substrate supply and has a knee osteoarthritis review Gupta 2025. Deliberately teaching the immune system to stop attacking a self antigen is a categorically different claim from reducing a cytokine.
- The compounds, last, and their evidence sits in named conditions rather than in autoimmunity generally. Curcumin has maintenance and induction trials in ulcerative colitis Hanai 2006 Lang 2015; palmitoylethanolamide has been meta-analyzed across double-blind randomized trials in chronic pain Lang-Illievich 2023; luteolin's mast-cell and microglial argument comes from animal work Burton 2016.
The order to run these in, and what has to be true first
Diagnosis first, then the two interventions with randomized evidence, then the condition-specific ones. The order is set by what the evidence is actually about rather than by how promising a mechanism sounds.
- A clinician and a diagnosis before anything on this page. One requisition alongside: ANA (Antinuclear Antibodies), Rheumatoid Factor, Thyroid Antibodies (TPO + TgAb) with Thyroglobulin Antibody, hs-CRP (High-Sensitivity C-Reactive Protein) with ESR (Sed Rate), Complete Blood Count (CBC) with Differential, Vitamin D (25-Hydroxy) and TSH (Thyroid-Stimulating Hormone). These are the numbers that will later tell you whether anything changed.
- Vitamin D and Omega-3 (Fish Oil) next, because they are the two items here with randomized incidence data Hahn 2022 and a published follow-up after the intervention ended Costenbader 2024. They are cheap, the trial doses were ordinary, and the effect is on developing disease rather than on curing it.
- Selenium only if the condition is autoimmune thyroiditis, and with the antibody question understood. The antibody reduction is established Gartner 2002; selenium has a narrow window between sufficiency and toxicity, so Selenium, Blood is worth measuring rather than assuming.
- Low Dose Naltrexone next, because it is cheap, low-risk and genuinely under-studied. A small randomized double-blind trial exists in fibromyalgia Younger 2013, a systematic literature review covers efficacy across conditions Partridge 2023, a more recent systematic review and meta-analysis addresses fibromyalgia specifically Vatvani 2024, and the immunometabolic effect has been examined in microglial cells Kučić 2021. It requires a prescription and a compounding pharmacy.
- UC-II Collagen next if joints are the presentation, because the mechanism is different from everything above it. Oral tolerance rather than anti-inflammatory action Gupta 2025, which means the dose is small and the timescale is months.
- Curcumin and Boswellia where the condition matches the trials, which is gut and joint. Curcumin has maintenance data in ulcerative colitis Hanai 2006 and an induction trial alongside mesalamine Lang 2015. Absorption is most of the argument, so the formulation matters more than the milligram figure.
- SPMs (Pro-Resolving Mediators) and Palmitoylethanolamide (PEA) are the resolution arm and sit here rather than higher because the human evidence is in pain rather than in autoimmunity Al-Shaer 2021 Lang-Illievich 2023. Luteolin is the mast-cell argument and is animal-stage Burton 2016.
- Thymosin Alpha 1, VIP and KPV are the peptide arm and are last. They modulate rather than stimulate, which is why they do not carry the concern that a true immune stimulant would, and the human evidence for the group in autoimmune indications is thin enough that this ordering is honest rather than dismissive.
What gets bought for this that cannot move it
The category that fails structurally is anything from the immune boosting half of this goal. Beta-glucans, mushroom extracts and colostrum are designed to make an innate response stronger, and this page exists because the response is already too strong. That is not a matter of degree; it is the wrong direction, and it is the reason Innate immunity & trained immunity is a separate pathway rather than a section of this one.
The surrogate on this page is the antibody titer, and this is the cleanest example of the problem on the whole site. Selenium lowers thyroid peroxidase antibodies Gartner 2002. The antibody is not what the patient has; the patient has a thyroid whose function is changing, and the questions that matter are whether TSH (Thyroid-Stimulating Hormone) and Free T4 (Thyroxine) move and whether replacement dose changes. A falling titer with a stable clinical picture is a real biochemical effect and an unproven clinical one, and both halves of that sentence are load-bearing. The extrapolation, and it is labeled as one, is that a lower titer should mean slower destruction over years; that trial has not been run.
The second failure is generalizing a condition-specific trial. Curcumin's evidence is in ulcerative colitis Hanai 2006 Lang 2015, palmitoylethanolamide's is in chronic pain Lang-Illievich 2023, undenatured collagen's is in knee osteoarthritis Gupta 2025. Autoimmunity is not one disease and these are not interchangeable results.
If the goal underneath is different, so is the page. If the problem is barrier and gut permeability, Barrier integrity & mucosal repair and Barrier & mucosal immunity. If it is joint pain without an autoimmune diagnosis, Synovial inflammation & pain. If mood is tracking the inflammation, Inflammation & the cytokine route to low mood. And new neurological symptoms, unexplained fever or a rapidly changing rash are an assessment today rather than a supplement decision.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Thyroid Antibodies (TPO + TgAb) falls on selenium in autoimmune thyroiditis and TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) may not move at all Gartner 2002, and that divergence is the information rather than a disappointment; and hs-CRP (High-Sensitivity C-Reactive Protein) with ESR (Sed Rate) is the pair that says whether anything systemic changed, because a symptom diary alone cannot distinguish a good month from a treated one.
- Thyroid Antibodies (TPO + TgAb) with TSH (Thyroid-Stimulating Hormone) and Free T4 (Thyroxine) at baseline and 6 months on selenium. Six months because the antibody response in the published work developed over months rather than weeks Gartner 2002, and because thyroid function equilibrates on its own slower schedule. Track all three, not the antibody alone.
- hs-CRP (High-Sensitivity C-Reactive Protein) with ESR (Sed Rate) at baseline and 12 weeks. These move on different timescales, which is why both are here: C-reactive protein responds within days and the sedimentation rate lags, so agreement between them is more convincing than either alone.
- Vitamin D (25-Hydroxy) at baseline and 12 weeks after a dose change. Twelve weeks because of the circulating half-life. This is the one intervention here with randomized incidence data behind it Hahn 2022, which makes achieving the trial-like status worth confirming.
- Selenium, Blood once before supplementing and once at 6 months. The window between sufficiency and toxicity is narrow enough that this is a safety measurement rather than an optimization one.
- Complete Blood Count (CBC) with Differential and Comprehensive Metabolic Panel (CMP) at baseline and 6 months, and a validated disease-activity score if one exists for your condition. The score is the endpoint the trials used; the bloods are there because several items on this page are taken alongside prescriptions that need monitoring.
What will fool you. Autoimmune disease relapses and remits, so starting anything during a flare guarantees an apparent improvement. C-reactive protein rises with any infection in the preceding fortnight. Antibody titers drift on their own and between assay platforms, so a single change is not a trend Gartner 2002. A curcumin product with a different absorption enhancer is a different exposure at the same milligram figure Lang 2015. Low-dose naltrexone is a different dose and a different literature from the licensed dose Partridge 2023. And an improvement that coincides with a change in a prescribed immunomodulator belongs to the prescription until proven otherwise.
Sources read for these sections
- Hahn J. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ 2022 · PMID 35082139
- Costenbader KH. Vitamin D and Marine n-3 Fatty Acids for Autoimmune Disease Prevention: Outcomes Two Years After Completion of a Double-Blind, Placebo-Controlled Trial. Arthritis and Rheumatology 2024 · PMID 38272846
- Gartner R, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. Journal of Clinical Endocrinology and Metabolism 2002;87(4):1687-1691 · PMID 11932302
- Younger J. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis and Rheumatism 2013;65(2):529-38 · PMID 23359310
- Partridge S, et al. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia. Heliyon 2023 · PMID 37206027
- Vatvani AD, et al. Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Korean Journal of Pain 2024 · PMID 39344363
- Kučić N, et al. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. International Journal of Molecular Sciences 2021 · PMID 34445130
- Hanai H. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006 · PMID 17101300
- Lang A. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015 · PMID 25724700
- Gupta A. Undenatured type II collagen for knee osteoarthritis. Annals of Medicine 2025;57(1):2493306 · PMID 40253594
- Lang-Illievich K. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients 2023 · PMID 36986081
- Al-Shaer AE. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Biochimica et Biophysica Acta Molecular and Cell Biology of Lipids 2021 · PMID 33794384
- Burton MD, Rytych JL, et al. Dietary Luteolin Reduces Proinflammatory Microglia in the Brain of Senescent Mice. Rejuvenation Research 2016 · PMID 26918466
The other 4 routes to immune resilience
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Immune resilience Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Immune resilience Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
The opposite problem, and one that 'immune boosting' actively worsens. Here the goal is restoring regulatory T-cell function and resolving inflammation properly — modulation rather than stimulation, and the distinction is not academic.
16 options are mapped to this pathway in the Vault, including Low Dose Naltrexone, VIP, KPV, Thymosin Alpha 1. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 11 carry clinical validation and 5 are mechanistic predictions.
Antibodies appear years before symptoms do. Thyroid antibodies in particular are worth knowing with a normal TSH, because they change how you'd approach iodine and selenium entirely. The markers worth checking are ANA (Antinuclear Antibodies), Rheumatoid Factor, Thyroid Antibodies (TPO + TgAb), hs-CRP (High-Sensitivity C-Reactive Protein).
Unproven is not the same as ineffective. Of the 16 options on this pathway, 11 have clinical validation and 5 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Autoimmunity & calming an over-active response. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.